AbbVie’s Skyrizi shows promise as personalised treatment for psoriasis
The immunosuppressant reduced inflammation in patients with the skin condition after three days
Read Moreby Jen Brogan | Feb 23, 2024 | News | 0
The immunosuppressant reduced inflammation in patients with the skin condition after three days
Read Moreby Jen Brogan | May 31, 2023 | News | 0
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
Read Moreby John Pinching | Sep 7, 2022 | News | 0
Positive data represents a boost for patients with moderate to severe plaque psoriasis
Read Moreby Lucy Parsons | Apr 26, 2021 | News | 0
Deucravacitinib demonstrated superior skin clearance compared with Otezla
Read Moreby Lucy Parsons | Nov 4, 2020 | News | 0
Deucravacitinib demonstrated superiority to placebo and Otezla in phase III
Read Moreby Lucy Parsons | Oct 16, 2020 | News | 0
Treatment demonstrated positive outcomes for nearly five years
Read Moreby Lucy Parsons | Sep 24, 2020 | News | 0
UCB is seeking approval for treatment in moderate-to-severe plaque psoriasis
Read Moreby Lucy Parsons | Aug 3, 2020 | News | 0
Low-dose and high-dose Cosentyx is effective in rapidly improving skin symptoms and quality of life
Read Moreby Anna Smith | Oct 9, 2019 | News | 0
Samsung Bioepis has announced real-world data from the drug.
Read Moreby Anna Smith | Aug 29, 2019 | News | 0
The Pharmacovigilance Risk Assessment Committee initially recommended new measures in July.
Read Moreby Anna Smith | Aug 12, 2019 | News | 0
The study is the first to compare Tremfya and the IL-17 inhibitor, Cosentyx.
Read Moreby Anna Smith | May 1, 2019 | News | 0
The approval is for the treatment of moderate to severe plaque psoriasis.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479